Inspired by true innovatorsRIBOPRO

Advanced CDMO services for nanomedicines

Ardena
Ardena is an integrated service CDMO, assisting biopharma companies with services spanning the full development life cycle. The company offers a comprehensive ‘Make, Analyze, File’ model from drug substance and drug product manufacturing and bioanalytical services through to regulatory dossier development.
With a strong reputation for quality and a flexible service delivery model, Ardena caters to a highly diversified base of over 500 customers throughout Europe, the US, Japan and Korea. A high science approach and broad drug development toolkit differentiate Ardena from peers as a comprehensive multi-service pan-European platform.

We work together on:

RIBOPRO provides advanced mRNA and LNP technologies to Ardena’s customers
Ardena support GMP development and regulatory approval of LNP formulations to RiboPro’s customers
Together, we provide an End-to-End solution for RNA therapy pioneers
Interested? Contact our BD-team via our dedicated contact page

RNA Readiness and Response

Wellcome Leap
The Wellcome Leap Health Breakthrough Network (HBNet) is the largest, most rapidly ‘activatable’ health research network in the world. With more than 100 world-class institutions, non-profits and commercial entities representing a network of over 1,000,000 scientists and engineers across six continents, they are able to increase speed and collaboration, reducing barriers to breakthroughs in human health.

We work together on:

Changing the dynamics and costs of development and production
Providing access to cGMP-formulated RNA
Producing at speeds & quantities sufficient for emergency situations
Learn more about Wellcome Leap

GMP-manufacturing sites

Medace
Medace is a Maastricht, the Netherlands, based service provider who helps companies like RIBOPRO start GMP-manufacturing. Medace provides services related to setting up a QMS, provides personnel for QA and manufacturing tasks if needed, takes care of warehousing and offers GMP-compliant cleanrooms (grade A, B and C) for rent.

We work together on:

RiboPro rents GMP-compliant cleanrooms (grade A & C)
Medace provides GMP-compliant warehousing
Medace provides support in setting up RIBOPRO’s QMS
Learn more about Medace

Targeted mRNA therapeutics

Mercurna
Mercurna is a Netherlands-based biotechnology company working on targeted mRNA therapeutics, with candidates for chronic kidney disease (CKD), eye disease, bone-marrow disease, and skin disease in preclinical development. Their most advanced program uses an unique kidney-targeting peptide (glomerulus targeting) with exceptional specificity, targeting a previously unknown receptor.

We work together on:

RiboPro supplies LNP & mRNA technologies to Mercurna
RiboPro manufactures mRNA & LNP for Mercurna
Mercurna provides specialized assays & targeting technology
Learn more about Mercurna

From molecule to patient

Radboudumc
The Radboudumc is based in Nijmegen, the Netherlands, and besides its clinical practises houses more than 45 research departments, of which multiple now use RIBOPRO mRNA for research and therapy development. To ensure commercial viability, Radboudumc and RIBOPRO entered a license agreement focussed that provides a framework for continuous access to RIBOPRO’s patented mRNA technologies.

We work together on (among others):

mRNA-supported CAR-T therapy
Kidney disease
LNP technologies
Learn more about Radboudumc

Partner with Professionals

Partnering with RIBOPRO
Partnering with RIBOPRO, as opposed to te more straight-forward customer-manufacturer relationship that we have with hundreds of customers, provides access to benefits such as priority manufacturing, extra financial/legal/product options, and contract research/co-development projects.

We like to work together on:

mRNA manufacturing (also saRNA, circRNA and next-gen long RNA)
LNP formulation
Enzyme development
Equipment development
Interested? Contact our BD-team via our dedicated contact page

RIBOPRO and ImmuneSpec are pleased to receive funding from CrossRoads Vlaanderen-Nederland to investigate the impact of mRNA therapies on immunogenicity. This collaboration brings together ImmuneSpec’s expertise in immunopeptidomics and RIBOPRO’s deep knowledge of mRNA design and manufacturing to advance the understanding of mRNA therapeutics.